The general mood among these heavyweight investors is divided, with 70% leaning bullish and 20% bearish. Among these notable ...

Amgen’s focus on blood cell medications continued in the 2000s, with the approval of Aranesp for the treatment of anaemic patients with chronic renal failure, and the 2002 approval of Neulasta ...

Aranesp, Neulasta, and Repatha, among others. On March 4, David Amsellem, analyst at Piper Sandler, reiterated a Buy rating ...

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Amgen's whale activity within a strike price range from $260.0 to $340.0 in the last 30 ...

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Investment analysts at William Blair issued their Q4 2026 earnings per share estimates for Amgen in a research report issued ...

Amgen (NASDAQ:AMGN – Free Report) had its price objective raised by Bank of America from $275.00 to $294.00 in a report released on Wednesday morning,Benzinga reports. Bank of America currently has an ...

Deep-pocketed investors have adopted a bullish approach towards Amgen (NASDAQ:AMGN), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled ...